"Semaglutide Reduces MACE, Death in Participants With CVD, Overweight/Obesity, and Impaired Kidney Function" Just presented at European diabetes meeting. Positive ozempic data in a non-diabetes population.
Commenting on the work, comoderator, Fiona Gribble, MBChB, DPhil, professor of endocrine physiology, University of Cambridge, UK, said: "I think the results showed very convincingly that semaglutide works very effectively in people with impaired kidney function as without."
Very well known link between obesity and FSGS, looks like Semaglutide could be a future option in FSGS.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
52.5¢ |
Change
-0.035(6.25%) |
Mkt cap ! $308.6M | |||
| Open | High | Low | Value | Volume |
| 56.5¢ | 57.0¢ | 52.0¢ | $1.033M | 1.931M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 18732 | 52.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.5¢ | 30517 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| DXB (ASX) Chart |